[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chf":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100578632","relive-randomized-evaluation-of-less-invasive-ventricular-enhancement-trial-100578632",false,"NCT06813820","RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial","RELIVE","Inclusion Criteria:\n\n1. 18 years old or older\n2. LV Aneurysm or Scar Presence: Defined by presence of a contiguous acontractile (akinetic and\u002For dyskinetic) non-calcified scar\n3. LV Aneurysm\u002FScar Location: Defined as a scar involving anterior, apical or anterolateral ± septal regions of the left ventricle as evidenced by cardiac imaging (Viability of myocardium in regions remote from area of intended scar exclusion as evidenced by cardiac imaging)\n4. Left Ventricular Ejection Fraction \\\u003C 40%\n5. Left ventricular end-systolic volume index ≥60 mL\u002Fm2\n6. Suffering from heart failure symptoms as defined by NYHA Classification \\> 2 not responsive to medical therapy\n7. Patient completed 6 Minute Walk Test and KCCQ Quality of Life Questionnaire (can be performed at baseline visit)\n8. Patient is on adequate Guideline Directed Medical Therapy (GDMT)\n9. Subject or a legally authorized representative must provide written informed consent\n10. Agree to required follow-up visits\n11. Female subject of childbearing potential does not plan pregnancy for at least one year following the index procedure. For a female of childbearing potential, a pregnancy test must be performed with negative results known within seven days prior to index procedure\n\nExclusion Criteria:\n\nCandidates will be excluded from the study if ANY of the following conditions is present:\n\n1. Cardiac Resynchronization Therapy (CRT) or ICD pacing lead placement ≤ 90 days prior to enrollment\n2. Valvular heart disease, which in the opinion of the investigator, will require intervention (transcatheter or surgical)\n3. Mitral Regurgitation greater than moderate (\\>2+)\n4. Need for coronary revascularization, in the opinion of the investigator\n5. Peak Systolic Pulmonary Arterial Pressure \\> 70 mm Hg via echo or right heart catheterization\n6. Myocardial Infarction within 90 days prior to enrollment\n7. Within the last six months, a prior CVA or TIA, or intracranial hemorrhage\n8. Co-morbid disease process with life expectancy of less than one year or active malignancy not in remission\n9. Severe pulmonary disease that would preclude general anesthesia\n10. Any solid organ transplant or is on waiting list for any solid organ transplant other than cardiac\n11. Chronic renal failure with a GFR\\\u003C30ml\u002Fmin\n12. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint","ALL","18 Years",{"count":19,"type":20},135,"ESTIMATED","INTERVENTIONAL",[23],"NA","A prospective, multi-center randomized trial comparing the Revivent System plus GDMT to GDMT alone. A total of approximately 135 subjects will be randomized in a 2:1 allocation ratio (90 treatment and 45 control), with approximately 128 evaluable patients and assuming 5% loss to follow-up. A primary safety endpoint will be evaluated at 30 days. Primary efficacy endpoint will be at 1 year. Interim efficacy endpoints will be evaluated at 6 months.",[26,27,28],"Left Ventricle Remodeling","Left Ventricle Dilated","CHF",[30],"Left Ventricle Reverse remodeling","RECRUITING","2026-02-19",{"date":34,"type":35},"2026-02-20","ACTUAL",{"date":37,"type":35},"2025-09-29",{"date":39,"type":20},"2032-08",{"name":41,"class":42},"BioVentrix","INDUSTRY",6,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100529112","salivary-extracellular-vesicle-associated-lncrnas-in-heart-failure-seal-hf-100529112","NCT06169540","Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)","SEAL-HF","Inclusion Criteria CHF:\n\n* At least 18 years of age\n* Stable disease defined as CHF of any type, New York Heart Association (NYHA) functional class II\u002FIII\u002FIV, N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥600 pg\u002Fml if Left Ventricular Ejection Fraction (LVEF) ≤30%; ≥1000 pg\u002FmL if LVEF 31-35%; ≥2500 pg\u002FmL if EF \\>35%\n\nInclusion Criteria ADHF:\n\n* At least 18 years of age\n* Clinical signs and\u002For symptoms (including exertional or rest dyspnea, orthopnea or Paroxysmal Nocturnal Dyspnea (PND)) and N-terminal pro-BNP level \\> 1000 pg\u002FmL or BNP \\> 400 pg\u002Fml, OR Clinical evidence of congestion: X-ray evidence of pulmonary edema or pleural effusions, elevated Jugular Venous Pulse (JVP), lower extremity edema, or rales on pulmonary examination, right heart catheterization evidence of elevated filling pressures (Right Atrium (RA) pressure \\> 10 mmHg; Pulmonary Capillary Wedge Pressure (PCWP) \\> 18 mmHg) and clinical response to Intravenous (IV) diuretic therapy (as judged by a physician)\n\nInclusion Criteria control:\n\n* At least 18 years of age\n* Will\u002Fhave undergone an EP procedure in the EP lab\n\nExclusion Criteria:\n\n* Active pregnancy or lactation\n* Cardiac amyloidosis\n* Active malignancies",{"count":52,"type":20},90,"OBSERVATIONAL","The purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blood and in the saliva of patients with Acute Decompensated Heart Failure (ADHF) and Chronic Heart Failure (CHF) to see if a new, non-invasive diagnostic test can be developed for heart failure exacerbation.",[28,56,57],"ADHF","Control","2025-11-11",{"date":60,"type":35},"2025-11-13",{"date":62,"type":35},"2023-04-19",{"date":64,"type":20},"2027-12-31",{"name":66,"class":67},"Massachusetts General Hospital","OTHER",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":99,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100354774","phase-1-safety-and-clinical-outcomes-with-amniotic-and-umbilical-cord-tissue-therapy-for-numerous-medical-conditions-100354774","NCT03899298","Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions","Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions","Inclusion Criteria:\n\n1. Age 18 and over.\n2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.\n3. Competent to understand the study protocol and provide voluntary informed consent.\n4. Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back\u002FNeck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.\n\nExclusion Criteria:\n\n1. Active Cancer\n2. Pregnancy, Lactating\n3. Severe Clotting disorder\n4. Myocardial Infarction less than six months ago.",true,{"count":78,"type":20},5000,[80],"PHASE1","To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.",[83,84,85,86,87,88,89,90,91,92,28,93,94,95,96,97,98],"Orthopedic Disorder","Neurologic Disorder","Urologic Diseases","Erectile Dysfunction","Autoimmune Diseases","Renal Failure","Renal Insufficiency","Kidney Diseases","Cardiac Event","Cardiomyopathies","Pulmonary Disease","COPD","Alzheimer Disease","Stroke","Neuropathy;Peripheral","Arthritis",[100,101,102,103,104,105,106,107],"stem cell therapy","umbilical stem cells","amniotic stem cells","stem cells","regenerative medicine","r3 stem cell","perinatal tissue","placenta stem cell","NOT_YET_RECRUITING","2019-08-20",{"date":111,"type":35},"2019-08-22",{"date":113,"type":20},"2019-09-01",{"date":115,"type":20},"2029-03-20",{"name":117,"class":42},"R3 Stem Cell"]